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CC BY-NC-ND license (http://creativeBackground: Group A streptococci (GAS) cause infections with a high prevalence in most devel-
oping countries. A GAS vaccine under trial that is based on the amino-terminus of the M protein
provides type-specific immunity, and hence seems ineffective in India because of heteroge-
neous emm types. However, the conserved C-terminal region of the M protein protects against
multiple serotypes. In this paper, the immune response generated against the conserved C-
repeat region of the M protein was checked in an Indian population to establish their vaccine
candidature.
Methods: When screened for GAS, patients with pharyngitis, rheumatic fever/rheumatic heart
disease (RF/RHD), and invasive disease showed heterogeneous emm types, out of which five
prevalent types (1-2, 11, 49, 75 and 112) were selected for the study. The C-terminal region
of their M proteins showed conserved C1-, C2-, and C3-repeats. The C1-repeat was more
diverse and had two different J14-like sequences. Peptides to these C-terminal regions
(J14.1 and J14-R6) were designed. Antibodies against these peptides were analyzed using
the sera of 130 GAS-infected volunteers.
Results: Serum antibodies were significantly higher in patients with acute rheumatic fever,
RHD, and invasive disease than in patients with pharyngitis or the healthy controls. The serum
antibodies to these peptides was higher in teenagers and adults than in children.t of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and
ail.com (A. Chakraborti).
.05.008
Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
Immunity against M protein of GAS 353Conclusion: Results showed an association between streptococcal disease progression and the
age-related development of immunity to the conserved regions. Hence, these peptides could
be considered protective in impeding streptococcal infections worldwide.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Group A streptococus (GAS; Streptococcus pyogenes) is
responsible for a wide spectrum of human infections
ranging from pharyngitis and impetigo to invasive diseases
such as streptococcal toxic shock-like syndrome, cellulitis,
and necrotizing fasciitis. The primary infections are self
limiting and innocuous. Of greater concern are post-
infectious sequelae such as aute rheumatic fever (ARF),
rheumatic heart disease (RHD), and acute glomerulone-
phritis,1 which are a cause of severe morbidity and mor-
tality in developing countries such as India.2,3 There is no
licensed vaccine available against GAS in the market. Thus,
a GAS vaccine that could prevent even a fraction of these
cases could have a major impact on the socioeconomic
status of the Indian population.
Intense research has unveiled a detailed understanding
of the molecular pathogenesis of GAS infections. Many
discoveries have identified several vaccine candidates,
which are in various stages of development.4e11 A leading
candidate antigen is the surface M protein, a major viru-
lence factor of GAS that confers protection against in-
fections in animal models.5,12e14 The M protein forms a
coiled-coil a-helix that consists of a hypervariable amino
terminal domain.15 Antibodies directed to this hypervari-
able region opsonize bacteria of homologous serotypes.
With the advent of serological diversity of the M types that
are isolated from patients with endemic disease, the main
efforts to develop a GAS vaccine have been hampered. To
date, more than 150 different emm types have been iden-
tified,16 which makes it impossible to effectively immunize
against the heterogeneous GAS strains. To develop a
broader strain coverage GAS vaccine, multivalent con-
structs have been investigated that use fused recombinant
amino terminal peptides derived from M protein associated
with epidemiologically important prevalent serotypes of
GAS.4,8,17 A 26-valent vaccine is undergoing clinical trials in
the United States of America.8 However, it seems quite
unlikely that it will provide protection to the Indian popu-
lation because different emm types are pervasive in India;
this indicates the need for the development of an indige-
nous/or universal vaccine.18
Another approach in designing a GAS vaccine has been to
investigate the highly conserved C-terminal region of the M
protein. In 2000, Cunningham reported that antibodies
directed to the C-terminal region protect against multiple
serotypes and hinder bacterial colonization at the mucosal
surface.1 Previous studies reveal opsonic antibodies specific
against the conserved C-terminal repeats of the M protein
in humans, and antibodies raised in mice to a conserved 20-
mer peptide (referred to as p145) have been known to
opsonize reference strains of GAS and GAS isolates fromAustralian aboriginal and Thai patients with rheumatic
fever.19,20 However, a few studies also indicate that p145
contain B cell and T cell epitopes and that T cell epitopes
share determinants on human cardiac myosin.20 However,
by placing overlapping segments of p145 within another
helical peptide derived from a yeast DNA-binding protein,
GCN4 (which is essential to sustain the exact helical folding
and conformational structure of the peptide), the peptide
J14 was mapped within p145 with minimal B cell epitope
and free from probable deleterious T cell autoepitopes.21
J14 (KQAEDKVKASREAKKQVEKALEQLEDRVK) is a peptide
with 14 amino acids from the C region of M proteins and is
flanked by yeast-derived GCN4 sequences. J14 seems to
elicit protective opsonic antibodies against multiple
different GAS isolates. It has been suggested that approxi-
mately 60% of GAS strains contain the J14 sequence, whereas
the remaining GAS strains contain J14-like sequences.13,22,23
Two peptide sequences, J8 and J14, from a conserved repeat
induce opsonic antibodies against multiple GAS strains.23 In
this study, to understand their potential as vaccine candi-
dates, the prevalent GAS emm types showing two peptides,
J14.1 and J14-R6 (which represent the J-14 like sequences),
were analyzed for their ability to elicit opsonic antibodies in
an Indian population with GAS infections.Methods
Screening of prevalent GAS isolates for J14 and
J14-like sequences from the conserved carboxy
terminal segment of the M protein
During the community surveillance from year 1997 to 2007,
throat samples (n Z 14019) and skin samples (n Z 3063)
were collected from patients who had pharyngitis, skin in-
fections, and ARF and resided in or around Chandigarh,
India. The samples were screened for GAS on blood agar
plates. The study was approved by Institute Ethics Com-
mittee, Post Graduate Institute of Medical Education and
Research, Chandigarh-160012, India (Ref. No. 43/IAEC/
177). A total of 407 cases of GAS infection were confirmed
by latex agglutination kits (Murex Kit, UK) and preserved
under proper storage conditions at the Department of
Experimental Medicine and Biotechnology at the Post-
graduate Institute of Medical Education and Research
(PGIMER) (Chandigarh, India). There were 70 types repre-
senting 53 known types, which included 33 subtypes, 12
sequence types, and five novel M-nontypable (MNT) strains.
The first 10 most prevalent emm typesd81, 11, 112, 77, 44,
15, 49, 75, NT, 1-2dcomprised 51.7% isolates. They were
screened for their national as well as worldwide preva-
lence18, based on which five types (i.e., emm 11, emm 112,
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present study. The most prevalent type was emm 81;
however, it was not included in this study since our earlier
study showed that emm 81 strains of North India are less
virulent with respect to adhesion and invasion.24
The genomic DNA of the GAS strains was isolated by a
modified SDS-phenol method.25 The emm gene was ampli-
fied as previously described.26,27 A pairwise comparison of
the nucleotide homology for the first 160 bases of the hy-
pervariable region of the emm gene against the bacterial
database (which can be accessed at http://www.cdc.gov/
ncidod/biotech/strep/strepblast.htm) was conducted to37
designate emm types to a particular strain. The obtained
nucleotide sequences of the conserved C-terminal segment
of the M protein (emm types 1-2, 11, 49, 75 and 112) were
subsequently deduced into amino acid sequences and
searched for J14 or J14-like sequences. The sequences and
number of their repeats were recorded.23
Synthesis of J-14 like sequence peptides
J14.1 (KQAEDKVKASREAKKKVEADLAQEEDKVK) and J14-R6P
(KQAEDKVKASRAAKKELENHQQEEDKVK),23 containing 29
amino acid sequences and 28 amino acid sequences,
respectively, were commercially synthesized by the fluo-
renylmethoxycarbonyl (FMOC) method from ISOGEN Life
Sciences (De Meern, Netherlands). Peptides were conju-
gated with Keyhole Limpet Hemocyanin (KLH; Boehringer
Mannheim, Germany) in the ratio of 1:10 and purified by
high pressure liquid chromatography (HPLC). Peptides were
dissolved in water at a concentration of 10 mg/mL and
maintained at 20C until use.
Estimation of human serum antibodies against J14-
like peptides
Blood sample collection
Blood samples were obtained after consent from 130 vol-
unteers from in and around Chandigarh, India who had
established RHD (n Z 40), ARF (n Z 40), pharyngitis
(n Z 40), and invasive disease (n Z 10). Blood from an
equal number of age- and sex-matched controls (n Z 130)
was also collected and their sera were segregated. Patients
having any other chronic illness or who did not give consent
for the sampling were excluded from the study. All patients
were assessed by physicians. The ARF patients were diag-
nosed on the basis of the revised Jones criteria28 and RHD
was diagnosed on the basis of echocardiography. The sera
were obtained during the acute stage of pharyngitis,
rheumatic fever, and invasive disease. The sera from pa-
tients with ARF and invasive disease was collected when
they were admitted for treatment in the hospital (i.e.,
PGIMER in Chandigarh, India). By contrast, the sera were
collected from RHD patients when the patients were
admitted to the hospital for valve replacement surgery.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was used to
measure human serum antibodies to the synthesized pep-
tides29 with the addition that standard curves of optical
density versus concentration of human immunoglobulin G(IgG) were used to calculate the antibody concentration.30
The peptides were initially diluted to 5 mg/mL in
carbonate-bicarbonate buffer (at pH 9.6), and coated onto
96-well ELISA plates (Nunc, Schwerte, Germany) in a volume
of 100 mL per well overnight at 4C. Excess antigen was
removed and the wells were blocked with 100 mL of 2%
bovine serum albumin in phosphate buffered saline (PBS) for
2 hours at 37C. Plates were washed five times with PBST
(PBS containing 0.05% Tween-20). Serum dilutions were
prepared in 1.0% skim milk in PBS, and 100 mL were added
and incubated for 1.5 hours at 37C. The plates were washed
five times with PBST and then incubated with rabbit-
antihuman IgG conjugated with horse-radish peroxidase
[(Bangalore Genei, India) (diluted 1:15000 in PBS-skim milk
(1.0%)] for 1.5 hours at 37C. The plates were washed five
times with PBSTand 100 mL of o-phenylenediamine substrate
was added and incubated for 30 minutes. The reaction was
stopped with 50 mL of 2N sulfuric acid (H2SO4) and the plates
were read at 450 nm in an ELISA plate reader.
Statistical analysis
The cross-reactivity was expressed as the arithmetic mean
and standard deviation. All statistical differences between
the control and different groups of GAS-infected patients
and between different age groups were assessed by the t
test for the unpaired mean. A p value of less than 0.05 was
considered statistically significant for all analyses.
Results
Identification of prevalent GAS types with J14 and/
or J14-like sequences
After sequencing the C-terminal region of prevalent emm
type encoding M protein and deducing the corresponding
amino acid sequences for the distribution of J14 and J14-
like sequences, it was observed that the selected emm
types contained the three C-repeats (i.e., C1 repeat, C2
repeat, and C3 repeat). The C1 repeat was more diverse
and contained two different J14-like sequences (i.e., J14.1
(ASREAKKKVEADLA) and J14-R6 (ASRAAKKELEANHQ). The
molecule J14-R6 was present in emm types 1-2, 11, 75, and
112, but was not present in emm 49.The C2- and C3-repeats
were identical with both having the J14.1 sequence (Fig. 1).
Our study showed that the J14.0 sequence was absent in
the C-repeat region for all the selected prevalent GAS
strains in the Indian population.
Prevalence of serum antibodies to J14.1 and J14-
R6 in an Indian population
The sera of healthy controls elicited a high antibody titer to
both peptides (J14.1 and J14-R6), even at 1:4000 dilutions.
The sera from patients with pharyngitis, ARF, RHD, and
invasive disease also had measurable levels (approximately
5 mg/mL) of serum antibodies to J14.1 and J14-R6. The
mean antibody concentration against these peptides was
similar in healthy controls and in patients with pharyngitis.
However, when compared to patients with pharyngitis, the
Figure 1. The J14 sequence types in the C-repeat region of the M protein of group A streptococci strains in a North Indian
population.
Figure 2. Analysis of the concentration of the serum anti-
body against J14.1 and J14-R6 in North Indian patients with
streptococcal infections and in healthy controls. ARF Z acute
rheumatic fever; Conc. Z concentration; RHD Z rheumatic
heart disease.
Immunity against M protein of GAS 355serum antibodies to these peptides were significantly
higher (approximately 8 mg/mL, p < 0.001) in patients with
ARF, RHD, and invasive disease (Fig. 2).
The sera of 130 Indian subjects with GAS infections were
categorized as “children” [i.e., patients aged 1e10 years
(n Z 28)], “teenager” [i.e., patients aged 11e20 years
(n Z 42)], and “adult” [i.e., patients aged over 20 years
(n Z 60)]. All three age groups contained detectable
quantities of anti-J14.1 antibodies (at 5.68 mg/mL, 7.14 mg/
mL and 6.82 mg/mL respectively) and anti-J14-R6 IgG an-
tibodies (at 5.63 mg/mL, 7.02 mg/mL, and 6.67 mg/mL for
anti-J14-R6 IgG antibodies, respectively). The teenagers
and adults had a significantly higher concentration of serum
antibodies to the two peptides, compared to the children
(p < 0.001) (Fig. 3).
Discussion
Studies from North Indian communities have shown a het-
erogeneous emm type distribution of GAS with seasonal,
Figure 3. Comparative analysis of the serum antibody con-
centration against J14.1 and J14-R6 peptides in an age-
stratified North Indian population.
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types were associated with the source of isolation.18 The
emm types circulating in North Indian communities differ
from those in south Indian communities and the developed
nations.8,16 The most prevalent emm types, comprising
51.7% isolates, were screened. Because emm 81 has been
shown to be less virulent,24 it was excluded from this study.
Selected for the present study were emm 11, which is a
common serotype that is often prevalent in the United
States and South India, along with the emm types 112 and
49, emm 1-2 (based on the role of emm 1 in invasive dis-
eases in developed nations), and emm 75 (which is preva-
lent in our region). Our past observations showed that only
50% of the emm types considered in the 26-valent multiple-
epitope vaccine were present in the North Indian commu-
nity. This suggests that the efficacy of current vaccines
under trial that are based on the N terminal region of M
proteins may not be successful in India.18 Therefore, we
considered the C-repeat conserved region of the M protein
in the present study to detect a vaccine candidate effective
against heterogeneous GAS strains, thereby making it a
universal vaccine.
All selected emm types showed the three C-repeats in a
conserved region of the M protein with the C1 repeat being
more diverse and containing J14.1 and J14-R6 sequences. In
another study, only 60% (12/20) of the isolates contained
three C-repeats, 35% contained two C-repeats, and one
isolate had a single C-repeat.23 The types emm 49 and emm
75 from a Northern Thai population.23 Our study interest-
ingly showed a similar C-repeat pattern, whereas an earlier
report from the same Indian region showed a variation in
the J14 sequence type.22 Among the 521 GAS isolates
examined in Fiji, most (91.6%) isolates had the three C-
repeats, 40 GAS isolates contained two C-repeats, and four
GAS contained only one C-repeat.11
In spite of the conserved sequence (greater than 98%),
variations have been reported towards the N-terminal re-
gion of the conserved C-repeat region,22,32 which was also
reflected in our study. Distribution of the J14 sequence in
isolates from the same geographical region have been
assessed that showed the C1-repeat had the greatest di-
versity (17 types) of J14 types; the C2 repeats containedthree J14 types (J14.1, 14.4, and 14.8) and C3-repeats
J14.1 type accounted for 72.7% isolates.22 Yoonim et al23
also found that the C1erepeat had the greatest diversity
(nine different types) of J14 types and the C2-repeat con-
tained eight different types of J14 types (with the greatest
being J14.1).The largest report of J14 sequence type from
Fiji identified 25 different J14 sequence types.11
Many studies show the potential of J14 to be a vaccine
candidate for GAS infection,22,33 although our study showed
that J14 sequence was absent in the C-repeat region for all
selected GAS strains. A few relevant studies also show that
the J14 epitope is present only within the C3-repeats.22,23
Four conserved J14 peptides, (i.e., J14, J14.1, J14-R1,
and J14.R2) are potential GAS vaccine candidates to pre-
vent streptococcal infections in an endemic area.23 Across
all C-repeat regions, 55 different J14 sequences types (i.e,
J14.0 to J14.54) have been described in Indian GAS iso-
lates.22 Fourteen new J14 sequence types (i.e., J14.55 to
J14.68) that have not been described previously have
recently been reported from Fiji,11 and have been
numbered in order of their discovery. In our study, and
similar to previous results, J14.1 and J14-R6 among the
different J14-like sequences are present in the C-repeat
region of the M protein.22 Antibodies raised against the
J14.0 peptide in mice opsonize the GAS strains belonging to
a variety of emm subtypes that contain J14 sequences other
than the J14.0 sequence type.22 Apart from GAS, 12 overall
J14 types among 248 GCS/GGS isolates have also been re-
ported,11 which makes these two J14 peptides promising
vaccine candidates against streptococcal infections in the
near future.
When serum antibodies to these peptides in patients
with ARF, RHD, and invasive disease were compared to
patients with pharyngitis, statistically significant results
were found. This suggests a greater immune response is
generated as the disease progresses towards chronicity. No
significant difference in the mean anti-p145 serum antibody
level has been recorded between RHD, ARF, and other
streptococcal diseases from Australian aborigines from a
highly endemic area,12 which is similar to our observation of
the same serum antibody concentration in patients with
ARF, RHD, and invasive disease.
Protective immunity from GAS is achieved through anti-
bodies directed against the M protein. Studies have provided
evidence that the relative resistance of adults to strepto-
coccal pharyngitis was not because of the presence of type-
specific antibodies, but may be because of the presence of
antibodies to the conserved determinants.33 In the present
study, all three age groups contained detectable quantities
of anti-J14.1 IgG and anti-J14-R6 IgG antibodies, respec-
tively. The teenagers and adults had a significantly higher
concentration of serum antibodies, compared to children.
The acquisition of antibodies to the conserved epitopes with
increasing in agemay explain, in part, the reduced incidence
rates of GAS infections and their sequelae in adults. These
observations are comparable to a previous study in which
adult sera showed strong antibody responses to the M6
protein-conserved region.34 Teenaged and adult aborigines
show significantly high serum antibody levels to the
conserved region epitope (i.e., p145, J1, J2, J3, J7, and J8),
compared to children.12 In the endemic areas, it has been
well established that children up to 10 years old have high
Immunity against M protein of GAS 357incidence rates of streptococcal skin and respiratory in-
fections, which decreases rapidly with increasing age.35 A
similar phenomenon has been observed in a case of
superantigen-mediated disease-toxic shock-like syndrome
(TSLS, in which a peptide was created from the homologous
region of staphylococcal enterotoxins and streptococcal
pyrogenic enterotoxins.36 The acquisition of antibodies
against p145 with age also paralleled the acquisition of GAS
immunity. This increases the likelihood of using this epitope
as a target in a prophylactic vaccine administered during
early childhood.12,29 Human sera with antibodies to p145
opsonize against heterologus GAS strains. However, p145
contains T cell epitope shared with determinants on human
cardiac myosin and keratin in the mouse.29 Henceforth, J14-
like sequences are searched for.
Thus, our data provide an insight into the development
of immunity against GAS with high antibody concentration
to conserved epitopes in the C-terminal region of M protein
as the infection progresses from pharyngitis to ARF, RHD,
and to an invasive state with increasing age. It appears that
immunization early in childhood with the peptides J14.1
and J14-R6 may induce accelerated immunity to many GAS
serotypes. However, considering that ARF/RHD is an auto-
immune disease, a potential risk associated with immuni-
zation with these peptides J14.1 and J14-R6 derived from M
protein may be that it might actually promote disease by
reacting with host tissues, including the heart. To develop a
successful antistreptococcal vaccine, it is vital to identify
epitopes that would provoke broad protection coverage
without evoking tissue cross-reactive antibodies. In this
study, we have identified the opsonic epitopes that are
particularly aimed to GAS-endemic areas that would offer
protection against multiple GAS strains and cover the wide
array of streptococcal infections in the Indian population.References
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